Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome-Pipeline Review, H2 2016, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.
Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 11, 62, 55, 3, 13 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 6, 7, 2, 1 and 2 molecules, respectively.Myelodysplastic Syndrome.
Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)
Key Topics Covered in the Report:
Myelodysplastic Syndrome Products Glance
Key Players In Myelodysplastic Syndrome Therapeutics
Myelodysplastic Syndrome Market Research Report
Myelodysplastic Syndrome Market Trends
Myelodysplastic Syndrome Overview
Myelodysplastic Syndrome Market Forecast
Myelodysplastic Syndrome Future Projections
Myelodysplastic Syndrome Competition Analysis
Myelodysplastic Syndrome Competitive Landscape
For more coverage click on the link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
